Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Neuroepidemiology ; 47(3-4): 155-163, 2016.
Article in English | MEDLINE | ID: mdl-27883994

ABSTRACT

BACKGROUND: Huntington's disease (HD) is a progressive neurodegenerative condition characterized by chorea, dystonia, behavioral disturbances and cognitive decline. The aim of this study is to assess temporal and spatial changes on mortality attributable to HD over 30 years in Spain. METHODS: HD data were extracted from the nationwide mortality registry for the period 1984-2013. Annual and 5-year gender- and age-specific rates adjusted for the standard European population were calculated. Geographic analysis was performed by districts from 1999 through 2013, and then estimated standardized mortality ratios (SMRs) and smoothed SMRs. RESULTS: There were 1,556 HD-related deaths across the study period. An increasing trend in age-adjusted HD mortality was in evidence, specifically from 1994 through 1998. On a year-by-year basis, age-adjusted mortality rates increased from 0.076 per 100,000 population in 1984 to 0.157 in 2013. Geographical differences among districts were evident in specific areas and in the southwest of Spain with a significantly higher HD mortality risk. CONCLUSION: HD mortality rising trends in Spain might be attributable to improvements in diagnosis leading to a rise in prevalence. Geographical variability in HD mortality could be related to regional differences in disease prevalence, health-care disparities, or other factors which call for in-depth assessment in future studies.


Subject(s)
Huntington Disease/mortality , Age Factors , Female , Geography , Humans , Male , Registries , Sex Factors , Spain , Time Factors
2.
Eur J Health Econ ; 15(4): 433-7, 2014 May.
Article in English | MEDLINE | ID: mdl-23839914

ABSTRACT

AIM: To assess the differences in the cost-effectiveness of oral triptan therapy for migraines among European countries. METHODS: A cost-effectiveness analysis of triptan therapy for migraine was conducted from a health-care payer perspective in four European countries (France, Italy, Spain and the UK). The study included those orally administered triptans available in all of these countries (almotriptan, brand-name sumatriptan, generic sumatriptan, zolmitriptan), and it was performed using a decision-tree model that incorporated costs of the drugs and probabilities associated with the possible events and outcomes. Average cost-effectiveness ratios were calculated in two different scenarios. RESULTS: The average cost-effectiveness ratio showed wide variations across the different countries, these differences being up to 131 % (almotriptan), 77 % (brand-name sumatriptan), 153 % (generic sumatriptan) and 77 % (zolmitriptan). Generic sumatriptan was the most cost-effective drug analysed in the studied countries. CONCLUSIONS: Caution must be taken when trying to transfer conclusions of pharmacoeconomics studies on migraines even in neighbouring countries. This cross-country variability is a concern for decision-makers and also for the elaboration of international recommendations and clinical practice guidelines.


Subject(s)
Migraine Disorders/drug therapy , Tryptamines/economics , Administration, Oral , Cost-Benefit Analysis , Decision Trees , Europe , Humans , Tryptamines/administration & dosage
3.
Neuroepidemiology ; 41(1): 13-9, 2013.
Article in English | MEDLINE | ID: mdl-23548700

ABSTRACT

BACKGROUND: Hereditary ataxias (HA) comprise a group of genetically heterogeneous rare diseases. As important public health problems to be monitored, this study analyses the morbimortality of HA in Spain. METHODS: Data were extracted from the national death index (1981-2008), using the International Classification of Diseases (ICD) 9th revision code 334 until 1998, and 10th revision code G11 from 1999 onwards. ICD-9 codes were then selected from the national discharge dataset (1998-2007). Age-adjusted morbidity and mortality rates were obtained by gender and 5-year period. RESULTS: Of the 610 HA deaths from 1981 to 2008, 277 corresponded to Friedreich's ataxia (45.4%) and 333 (54.6%) to other and unspecified ataxias (non-Friedreich group). Both groups showed an increase in mortality trend, which was more pronounced in males from 1985-1989 to 1990-1994. Geographical distribution of mortality revealed higher risk for males, mainly in the north of Spain. A total of 5,341 HA hospitalisations were identified from 1998 to 2007. The average annual age-adjusted hospitalisation rate was 1.19 per 100,000 population, with a rising trend. CONCLUSION: This increase in morbidity and mortality, coupled with the slight interprovincial differences, indicate that more attention should be paid to these rare diseases by public authorities and society alike.


Subject(s)
Patient Discharge/statistics & numerical data , Spinocerebellar Degenerations/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Cause of Death , Child , Child, Preschool , Female , Humans , Infant , International Classification of Diseases , Male , Middle Aged , Prevalence , Registries , Spain/epidemiology , Spinocerebellar Degenerations/mortality
4.
Community Dent Oral Epidemiol ; 40(2): 185-92, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22044166

ABSTRACT

OBJECTIVE: To study the cost-effectiveness of four alternative treatments for burning mouth syndrome (BMS). METHODS: A cost-effectiveness analysis was conducted from a healthcare payer perspective of four therapy strategies (amisulpride, paroxetine, sertraline and topical clonazepam), using a decision-tree model that incorporated direct healthcare costs and probabilities associated with the possible events and outcomes. Average cost-effectiveness and incremental cost-effectiveness ratios were calculated. Sensitivity analyses included the costs of brand name and generic drugs in five European countries (France, Italy, the Netherlands, Spain and UK), as well as two scenarios with different treatment length. RESULTS: Of the drugs analysed, topical clonazepam proved to be the most cost-effective therapy. Although generic proved more efficient than brand name drugs, they displayed no advantage over brand name topical clonazepam. The Netherlands was the country with the highest overall drug efficiency. Sensitivity analyses highlighted the robustness of the model, because topical clonazepam proved to be the most efficient therapy under all the different scenarios. CONCLUSIONS: Topical clonazepam, which previous analyses of clinical evidence have shown to be the drug of choice for BMS, also proved to be the most cost-effective of the drugs analysed for this condition.


Subject(s)
Burning Mouth Syndrome/economics , Amisulpride , Antidepressive Agents/economics , Antidepressive Agents/therapeutic use , Burning Mouth Syndrome/drug therapy , Clonazepam/economics , Clonazepam/therapeutic use , Cost-Benefit Analysis , Decision Trees , Dental Care/economics , Drug Costs/statistics & numerical data , Health Care Costs/statistics & numerical data , Humans , Paroxetine/economics , Paroxetine/therapeutic use , Sertraline/economics , Sertraline/therapeutic use , Sulpiride/analogs & derivatives , Sulpiride/economics , Sulpiride/therapeutic use
5.
Amyotroph Lateral Scler ; 12(3): 192-8, 2011 May.
Article in English | MEDLINE | ID: mdl-21198417

ABSTRACT

The aim of this study was to assess the trend of motor neuron disease mortality in Spain from 1990 to 2005, and to ascertain the existence of geographical differences in mortality rates. MND deaths are registered by the National Statistics Institute of Spain ­ International Classification of Diseases (ICD) codes ICD9 335.2 (1990-1998) and ICD10 G12.2 (1999-2005). Annual sex- and age-specific rates, as well as rates adjusted for the standard European population were obtained. Provincial standardized mortality ratios (SMRs) were calculated for the study period. Respective provincial SMRs were smoothed with data from adjacent provinces using a Poisson model. Results showed that MND mortality increased in Spain from 1990 to 2005. Geographical differences between provinces were evident throughout the study period. In general, risk of death due to MND was higher in regions lying to the north of Spain. In conclusion, the temporal and geographical variability observed might be explained by genetic factors, differences in environmental exposures and the possible influence of the type of medical care and treatment received. Mortality depends also on health service quality and diagnostic validity. All these factors may play a very important role in analysis of MND mortality in Spain, and the contribution of each of these will have to be examined in depth by ad hoc studies.


Subject(s)
Geography , Motor Neuron Disease/mortality , Aged , Environmental Exposure , Female , Health Services , Humans , Male , Middle Aged , Motor Neuron Disease/diagnosis , Motor Neuron Disease/therapy , Registries , Spain/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...